Cargando…
Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
The effect has been studied of adding either misonidazole (MISO) or the radioprotective drug, WR 2721, to cyclophosphamide (CY) treatment of mice bearing either the RIF-1 or KHT sarcomas. In RIF-1, the growth delay due to CY was increased by the addition of 1 mg/g of MISO. At doses below 75 mg/kg of...
Autor principal: | Twentyman, P. R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1981
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010713/ https://www.ncbi.nlm.nih.gov/pubmed/6264941 |
Ejemplares similares
-
Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
por: Rojas, A., et al.
Publicado: (1983) -
The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.
por: McNally, N. J.
Publicado: (1982) -
Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse.
por: Twentyman, P. R.
Publicado: (1983) -
Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
por: Yuhas, J. M., et al.
Publicado: (1980) -
Antiretroviral activity of aminothiols, WR2721 and WR1065
por: Poirier, Miriam C, et al.
Publicado: (2006)